"Also look at page 21,  not a very big sample....."

That's why they called this an exploratory analysis. 

I'm impressed. In diabetic, recent ACS patients 70 years or older w/ baseline MoCA <22, apabetalone elicited a statistically significant 158% increase in MoCA vs. placebo in BETonMACE cognition sub-study. Mutliple domains of the MoCA test were improved. Benefit for those w/ baseline MoCA <22 apparent at end of study (~2 years) and not at 52 weeks. No effect of apabetalone in those w/ baseline MoCA >25; a trend for benefit in those w/ baseline MoCA between 22 and 25.

BDAZ